New York Xaljenz Thrombosis Lawyers

Xaljenz (Tofacitinib) Pulmonary Embolisms

Have you or a loved one experienced a blood clot, deep vein thrombosis or pulmonary embolism while using Xaljenz sold by Pfizer? The drug was approved by the FDA in 2012. Xaljenz is one of the new “JAK Inhibitors” (janus kinase) used to treat moderate-to-severe active rheumatoid arthritis, psoriatic arthritis and moderate-to-severe active ulcerative colitis.

A Rheumatology Data Safety Monitoring Board stated in February 2019 that patients who received the 10 mg dose of Xaljenz were at a higher risk of pulmonary embolism and death, compared with patients in this study who were treated with a similar drug.

Our attorneys, Paul Rheingold and David Rheingold, have decades of litigation experience involving pulmonary embolism injuries, particularly with hormonal birth control, testosterone and inferior vena cava medical devices. Our firm has represented thousands of clients and gained millions of dollars in verdicts and settlements for other prescription drug cases.

Contact us to speak with a drug litigation partner from a
New York pharmaceutical litigation law firm.

Thrombois Warnings in Europe for Another JAK (Janis Kinase) Drug Sold to Treat Rheumatoid Arthritis

A thrombosis is a potentially life-threatening blood clot that can start in the leg and then travel to the lungs. The European Drug Agency required the following warning on a similar Janus Kinase inhibitor drug which treats rheumatoid arthritis:

THROMBOSIS: “Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. Patients with symptoms of thrombosis should be promptly evaluated.”

Is an FDA Warning Coming for Rheumatoid Arthritis Drugs for Deep Vein Thrombosis and Pulomanry Embolism Injuries and Deaths?

Independent medical groups have been publishing articles since 2017 based on FDA adverse event data reporting (known as FAERS data) documenting clot injuries in patients using this class of drug. One study suggested the adverse event reports indicated that pulmonary thrombosis may be a class-wide issue for JAK inhibitors. Researchers want future studies to focus on dosage, other drugs being used, pre-existing conditions and larger placebo groups.

New York Firm Experienced in Dealing with Pharmaceutical Companies

Our firm has extensive litigation experience against Pfizer and other companies marketing drugs associated with pulmonary embolisms. Our New York defective drug attorneys handle a wide range of drug liability claims, including those involving the prescription drug Xeljanz. Call (888) 260-0473 for a free case evaluation.

Please contact us today online or by telephone at (888) 260-0473 to speak with an experienced New York drug liability law firm.

Results Feed Header

Prev Next

Don't Settle

for an Average Attorney
    • Please enter your name.
    • This isn't a valid phone number.
    • Please enter your email address.
      This isn't a valid email address.
    • Please make a selection.
    • Please enter a message.
Get RGRP On Your Side